Hematologic Oncology Abstracts to Watch at the 2025 ESMO Congress

Although the 2025 ESMO Congress will be dominated by key data and updates across a variety of solid tumors, the conference will feature its share of updates and studies within the hematologic oncology realm.

To prepare for the meeting, OncLive^® took a look at all of the oral abstracts related to hematologic malignancies being presented during a pair of sessions at the meeting. Read on below to see some of the hematologic oncology oral abstracts being presented across these 2 sessions at the 2025 ESMO Congress.

Proffered Paper Session: Haematological Malignancies

Date: Friday, October 17, 2025

Time: 2:00 PM to 3:30 PM CEST

1240O – CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory Large B-cell Lymphoma: a Prospective, Single-arm, Single-center, Phase 2 Clinical Trial

This prospective, single-arm, single-center phase 2 study (NCT06081478) is evaluating a novel CD19- and CD22-directed bispecific CAR T-cell therapy in patients 14 to 85 years of age with CD19- and CD22-positive B-cell lymphoma or B-cell acute lymphoblastic leukemia that is relapsed/refractory after standard-of-care first-line therapy.¹ All enrolled patients received the bispecific CAR T-cell therapy as a single infusion, administered at 2.0 x 10⁶ CD19-positive cells/kg and 1.0 x 10⁶ CD22-positive cells/kg. The study’s primary end point is overall response rate (ORR).

Previously reported data from the phase 2 study presented at the 2025 EHA Congress demonstrated that the bispecific CAR T-cell therapy produced a favorable safety profile and efficacy in patients with relapsed/refractory large B-cell lymphoma.²

1241O – Anti-PD-1-Antibody (Tislelizumab) Combined with Chidamide, Lenalidomide and Etoposide for the treatment of refractory/relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r-ENKTL): Preliminary Results from a Prospective, Multicenter, Single-Arm, Phase II Trial

A prospective, open-label, single-arm, multicenter phase 2 trial (NCT04038411) being conducted in China is evaluating the combination of tislelizumab (Tevimbra), chidamide (tucidinostat; HBI-8000), lenalidomide (Revlimid), and etoposide in patients 14 to 65 years of age with relapsed/refractory natural killer/T-cell lymphoma after at least 2 prior lines of therapy.³ To enroll, patients needed to have an ECOG performance status of 0 to 2, a life expectancy of at least 3 months, and at least 1 measurable lesion.

All patients received tislelizumab at 240 mg on day 1, chidamide at 20mg twice per week, lenalidomide at 25mg per day on days 1 to 14, and etoposide at 100mg/m² on days 1 to 3 of each 21-day cycle. ORR served as the trial’s primary end point.

1242O – Sustained marrow and imaging MRD negativity can lead to lenalidomide discontinuation following ASCT in multiple myeloma: Updated results from a prospective cohort study

Mini Oral Session: Haematological Malignancies

Date: Sunday, October 19, 2025

Time: 8:30 AM to 10:00 AM CEST

1243MO – Risk Stratification for Diffuse Large B-Cell Lymphoma by Integrating Interim 18F-FDG PET-CT Analysis and the NCCN-IPI: A Multicentre Retrospective Study

In this retrospective study conducted in China, investigators analyzed the clinicopathological and PET-CT data of 498 patients diagnosed with diffuse LBCL (DLBCL) in order to assess the prognostic significance of the interim National Comprehensive Cancer Network International Prognostic Index and PET-CT–related parameters in order to better stratify patients by risk and predict outcomes.⁴

1245MO – Combination of Mitoxantrone Hydrochloride Liposome with Chidamide in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma: Updated Results of the Phase II Study

This presentation will feature updated results from the phase 2 portion of a phase 1/2 trial (NCT05527275) evaluating mitoxantrone hydrochloride liposome plus chidamide in patients with relapsed/refractory peripheral T-cell lymphoma.⁵ Previously reported data from the study demonstrated that the combination produced promising efficacy and manageable safety in this patient population.

The study included patients 18 to 75 years of age with histologically confirmed PTCL non-specific type, angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma, anaplastic large cell lymphoma, and other subtypes of PTCL.⁶ Patients needed to have relapsed/refractory disease, measurable disease, and an ECOG performance status of 0 to 2. Following the dose-escalation portion in phase 1, patients received the combination at the recommended phase 2 dose in the second portion. ORR was the primary end point for phase 2.

1249MO – Macrophage reprogrammer Bexmarilimab Plus Azacitidine in Myelodysplastic Syndrome: PK/PD and biomarker results from the Phase 1/2 BEXMAB Study

The phase 1/2 BEXMAB trial (NCT05428969) is evaluating the combination of bexmarilimab and azacitidine in patients with higher-risk myelodysplastic syndrome (MDS). Data presented at the 2025 ASCO Annual Meeting showed that no grade 5 adverse effects related to bexmarilimab were reported.⁷ Patients with relapsed/refractory disease also experienced a median overall survival of 13.4 months. The ORRs in the treatment-naive and relapsed/refractory patient populations were 72% and 63%, respectively.

Other Presentations

1246MO – Single-Cell Atlas of Circulating Immunity identifies shared specific DLBCL signatures for predicting Response to R-CHOP and Anti-CD19 CAR T Therapies

1247MO – Molecular Landscape of Distinct Follicular Lymphoma Histologic Grades: Insights from Genomic and Transcriptome Analyses

1248MO – Changes in Peripheral Blood Leukemia Stem Cells, Immune Cell Subsets, Cytokines, and Cellular Differentiation Status Before and After Venetoclax-Containing Regimen Treatment for Acute Myeloid Leukemia

1250MO – Outcomes of Patients with Chronic Myeloid Leukemia Receiving Second-Line Therapy

References

1. CD19/​CD22 bispecific CAR-T cell therapy for relapsed/​refractory B-cell lymphoma or acute lymphoblastic leukemia. ClinicalTrials.gov. Updated October 13, 2023. Accessed September 29, 2025. https://clinicaltrials.gov/study/NCT06081478
2. Liu X, Cong J,Wang L, et al. CD19/CD22 bispecific CAR-T cell therapy for relapsed/refractory large B-cell lymphoma: a prospective, single-arm, single-center, phase 2 clinical trial. Presented at: 2025 EHA Congress; June 12-15, 2025; Milan, Italy. Abstract PF1157.
3. PD-1 antibody, chidamide, lenalidomide and etoposide for relapsed or refractory NK/​T cell lymphoma. ClinicalTrials.gov. Updated July 30, 2019. Accessed September 29, 2025. https://clinicaltrials.gov/study/NCT04038411
4. Wang J, Sun Y, Lin M, et al. Risk Stratification for Diffuse Large B-Cell Lymphoma by Integrating Interim 18F-FDG PET-CT Analysis and the NCCN-IPI: A Multicenter Retrospective Study. Hematol Oncol. 2025;43(4):e70118. doi:10.1002/hon.70118
5. Li Z, Sun P, Yang H, et al. Combination of mitoxantrone hydrochloride liposome with chidamide in patients with relapsed or refractory peripheral T cell lymphoma: A phase l/II study. Ann Oncol. 2024;35(suppl 2):S600. doi:10.1016/j.annonc.2024.08.861
6. Mitoxantrone hydrochloride liposomes in combination with GDP in relapsed/​refractory PTCL. ClinicalTrials.gov. Updated July 1, 2022. Accessed September 29, 2025. https://clinicaltrials.gov/study/NCT05441761
7. Daver N, Kontro M, Rimpiläinen J, et al. Efficacy of macrophage checkpoint Clever-1 inhibition with bexmarilimab plus azacitidine in myelodysplastic syndrome: Results from the ph1/2 BEXMAB study. J Clin Oncol. 2025;43(suppl 16): 6513. doi:10.1200/JCO.2025.43.16_suppl.6513